Aberdeen Group plc Increases Holdings in Abbott Laboratories $ABT

Aberdeen Group plc increased its position in Abbott Laboratories (NYSE:ABT) by 1.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,993,536 shares of the healthcare product maker’s stock after purchasing an additional 23,817 shares during the quarter. Aberdeen Group plc owned approximately 0.11% of Abbott Laboratories worth $249,770,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. Brighton Jones LLC increased its holdings in shares of Abbott Laboratories by 10.1% in the 4th quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker’s stock valued at $5,850,000 after acquiring an additional 4,755 shares during the period. Sivia Capital Partners LLC lifted its position in shares of Abbott Laboratories by 3.5% during the second quarter. Sivia Capital Partners LLC now owns 4,768 shares of the healthcare product maker’s stock valued at $648,000 after buying an additional 162 shares during the last quarter. United Bank boosted its holdings in shares of Abbott Laboratories by 7.4% in the 2nd quarter. United Bank now owns 29,004 shares of the healthcare product maker’s stock valued at $3,945,000 after buying an additional 2,001 shares in the last quarter. Edgestream Partners L.P. purchased a new position in shares of Abbott Laboratories in the 2nd quarter worth approximately $404,000. Finally, Arrowstreet Capital Limited Partnership raised its stake in shares of Abbott Laboratories by 134.2% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 509,565 shares of the healthcare product maker’s stock worth $69,306,000 after acquiring an additional 291,987 shares in the last quarter. 75.18% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, Director Daniel J. Starks acquired 10,000 shares of the stock in a transaction on Wednesday, February 4th. The shares were acquired at an average price of $108.73 per share, for a total transaction of $1,087,300.00. Following the transaction, the director owned 6,738,817 shares in the company, valued at approximately $732,711,572.41. This trade represents a 0.15% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP John A. Jr. Mccoy sold 585 shares of the firm’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $67,614.30. Following the sale, the vice president directly owned 24,628 shares in the company, valued at $2,846,504.24. The trade was a 2.32% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 3,055 shares of company stock valued at $353,097 in the last three months. 0.46% of the stock is currently owned by company insiders.

Trending Headlines about Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott joined Whoop’s $575M Series G as a strategic investor, linking its diagnostics/device expertise to Whoop’s consumer wearable and insights platform — a move that could accelerate Abbott’s digital-health footprint and recurring-data opportunities. Abbott’s Whoop Investment Puts Digital Health Wearables On Shareholders’ Radar
• Positive Sentiment: Trade press confirms the Whoop deal and frames it as a strategic partnership to “empower people to take control of their health,” reinforcing investor interest in recurring-data and consumer channels. Abbott joins $575M funding round for wearable maker Whoop
• Neutral Sentiment: Several analyst pieces and screeners are revisiting ABT’s valuation and earnings setup (comparisons with GE HealthCare, “reasons to retain” commentary, trending-stock writeups). These note durable FreeStyle Libre growth and a Nutrition rebound but warn currency/macro headwinds — evidence that views are mixed rather than uniformly bullish. GEHC or ABT: Which Is the Better Value Stock Right Now?
• Positive Sentiment: At least one outlet upgraded Abbott’s investment case heading into Q1 earnings, highlighting the company’s diversified franchise and margin/growth outlook — a potential tailwind if Q1/guide reassure investors. Abbott: A Brighter Investment Case Heading Into Q1 Earnings (Rating Upgrade)
• Negative Sentiment: BTIG lowered expectations for ABT’s stock price, adding analyst pressure that could cap gains until management proves guidance/organic growth trajectory. BTIG Research Has Lowered Expectations for Abbott Laboratories (NYSE:ABT) Stock Price
• Negative Sentiment: Coverage noting that Abbott is ~26% below its 52-week high after a soft quarter underscores investor concern about near-term topline pressure despite long-term dividend credibility. This Dividend King Is Down 26%. When Will It Bounce Back?

Abbott Laboratories Trading Up 0.4%

Abbott Laboratories stock opened at $102.84 on Friday. The stock has a 50-day moving average price of $109.57 and a 200 day moving average price of $121.31. The company has a market capitalization of $179.11 billion, a price-to-earnings ratio of 27.65, a price-to-earnings-growth ratio of 1.63 and a beta of 0.79. Abbott Laboratories has a 52 week low of $100.88 and a 52 week high of $139.06. The company has a quick ratio of 1.18, a current ratio of 1.58 and a debt-to-equity ratio of 0.19.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share for the quarter, hitting the consensus estimate of $1.50. The company had revenue of $11.46 billion for the quarter, compared to the consensus estimate of $11.80 billion. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.73%. Abbott Laboratories’s quarterly revenue was up 4.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.34 EPS. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Sell-side analysts anticipate that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be given a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 2.5%. The ex-dividend date is Wednesday, April 15th. Abbott Laboratories’s dividend payout ratio (DPR) is currently 67.74%.

Analysts Set New Price Targets

Several research firms have issued reports on ABT. Royal Bank Of Canada cut their price target on shares of Abbott Laboratories from $147.00 to $135.00 and set an “outperform” rating on the stock in a report on Friday, January 23rd. Raymond James Financial dropped their target price on Abbott Laboratories from $146.00 to $130.00 and set an “outperform” rating on the stock in a research note on Friday, January 23rd. Citigroup reduced their target price on Abbott Laboratories from $140.00 to $136.00 and set a “buy” rating on the stock in a research report on Wednesday, March 11th. Oppenheimer lowered their price target on Abbott Laboratories from $140.00 to $132.00 and set an “outperform” rating for the company in a report on Friday, January 23rd. Finally, The Goldman Sachs Group dropped their price target on Abbott Laboratories from $152.00 to $140.00 and set a “buy” rating on the stock in a research note on Friday, January 23rd. Two research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $135.68.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.